News

Johnson & Johnson works on SARS-CoV-2

Mar 23, 2020
Johnson & Johnson is mobilizing resources of its Janssen Pharmaceutical Companies in response to the outbreak to develop a possible preventive vaccine candidate against SARS-CoV-2, leveraging Janssen's AdVac® and PER.C6® technology, that provide the ability to rapidly upscale production of the optimal vaccine candidate. These are the same technologies that were used in the development and manufacturing of Janssen's investigational Ebola vaccine, which is currently deployed in the Democratic Republic of the Congo and Rwanda, and were also used to construct the Company's Zika, RSV and HIV vaccine candidates.

The Company announced on February 18, 2020 that Janssen Pharmaceutical Companies will expand its existing partnership with the Biomedical Advanced Research and Development Authority (BARDA), part of the Office of the Assistant Secretary for Preparedness and Response (ASPR) at the U.S. Department of Health & Human Services, to seek treatment solutions for COVID-19.

Johnson & Johnson has robust business continuity plans in place across its global supply chain network to prepare for unforeseen events like the coronavirus outbreak. We are closely monitoring product demand and supply levels across our global network to ensure adequate and effective distribution, and working diligently to meet patient, customer and consumer need.

< Back to News

Categories

Swedbank

Feedback

AmCham is an invaluable resource that keeps us up to date with business issues and opportunities.

Mantautas Paskevicius, Country Manager of Strategic Staffing Solutions International

We re-affirm our commitment to the values that AmCham stands for and that we share.

Kārlis Danēvičs, Board member, Head of Credits and Risk at SEB Banka